AbbVie annual r&d spending
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
AbbVie R&D Spending Growth & History (ABBV)
AbbVie's r&d spending was $9.10B for fiscal 2025.
View full AbbVie company overviewAbbVie annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $9.10B | −$3.69B | −28.89% |
| 2024 | 2024-12-31 | $12.79B | $5.12B | +66.66% |
| 2023 | 2023-12-31 | $7.67B | $1.17B | +17.90% |
| 2022 | 2022-12-31 | $6.51B | −$412.0M | −5.95% |
| 2021 | 2021-12-31 | $6.92B | $543.0M | +8.51% |
| 2020 | 2020-12-31 | $6.38B | −$28.0M | −0.44% |
| 2019 | 2019-12-31 | $6.41B | −$3.92B | −37.97% |
| 2018 | 2018-12-31 | $10.33B | $5.32B | +106.29% |
| 2017 | 2017-12-31 | $5.01B | $622.0M | +14.18% |
| 2016 | 2016-12-31 | $4.38B | $100.0M | +2.33% |
| 2015 | 2015-12-31 | $4.29B | $988.0M | +29.97% |
| 2014 | 2014-12-31 | $3.30B | $442.0M | +15.48% |
| 2013 | 2013-12-31 | $2.85B | $77.0M | +2.77% |
| 2012 | 2012-12-31 | $2.78B | $160.0M | +6.11% |
| 2011 | 2011-12-31 | $2.62B | — | — |
AbbVie quarterly r&d spending
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.34B | $213.0M | +10.00% |
| Q1 2026 | 2026-03-31 | $2.47B | $405.0M | +19.59% |
| Q4 2025 | 2025-12-31 | $2.58B | −$4.20B | −61.93% |
| Q3 2025 | 2025-09-30 | $2.32B | $189.0M | +8.87% |
| Q2 2025 | 2025-06-30 | $2.13B | $183.0M | +9.39% |
| Q1 2025 | 2025-03-31 | $2.07B | $128.0M | +6.60% |
| Q4 2024 | 2024-12-31 | $6.77B | $4.85B | +251.53% |
| Q3 2024 | 2024-09-30 | $2.13B | $407.0M | +23.62% |
| Q2 2024 | 2024-06-30 | $1.95B | $215.0M | +12.41% |
| Q1 2024 | 2024-03-31 | $1.94B | −$353.0M | −15.40% |
| Q4 2023 | 2023-12-31 | $1.93B | $137.0M | +7.65% |
| Q3 2023 | 2023-09-30 | $1.72B | $109.0M | +6.75% |
| Q2 2023 | 2023-06-30 | $1.73B | $124.0M | +7.71% |
| Q1 2023 | 2023-03-31 | $2.29B | $795.0M | +53.11% |
| Q4 2022 | 2022-12-31 | $1.79B | −$37.0M | −2.03% |
| Q3 2022 | 2022-09-30 | $1.61B | −$47.0M | −2.83% |
| Q2 2022 | 2022-06-30 | $1.61B | −$158.0M | −8.94% |
| Q1 2022 | 2022-03-31 | $1.50B | −$170.0M | −10.20% |
| Q4 2021 | 2021-12-31 | $1.83B | $115.0M | +6.72% |
| Q3 2021 | 2021-09-30 | $1.66B | −$45.0M | −2.64% |
| Q2 2021 | 2021-06-30 | $1.77B | $185.0M | +11.69% |
| Q1 2021 | 2021-03-31 | $1.67B | $288.0M | +20.88% |
| Q4 2020 | 2020-12-31 | $1.71B | $170.0M | +11.02% |
| Q3 2020 | 2020-09-30 | $1.71B | −$579.0M | −25.34% |
| Q2 2020 | 2020-06-30 | $1.58B | $291.0M | +22.54% |
| Q1 2020 | 2020-03-31 | $1.38B | $90.0M | +6.98% |
| Q4 2019 | 2019-12-31 | $1.54B | −$4.95B | −76.26% |
| Q3 2019 | 2019-09-30 | $2.29B | $1.02B | +80.21% |
| Q2 2019 | 2019-06-30 | $1.29B | −$31.0M | −2.34% |
| Q1 2019 | 2019-03-31 | $1.29B | $45.0M | +3.62% |
| Q4 2018 | 2018-12-31 | $6.50B | $5.09B | +361.29% |
| Q3 2018 | 2018-09-30 | $1.27B | $40.0M | +3.26% |
| Q2 2018 | 2018-06-30 | $1.32B | $93.0M | +7.57% |
| Q1 2018 | 2018-03-31 | $1.24B | $102.0M | +8.93% |
| Q4 2017 | 2017-12-31 | $1.41B | $199.0M | +16.46% |
| Q3 2017 | 2017-09-30 | $1.23B | $122.0M | +11.03% |
| Q2 2017 | 2017-06-30 | $1.23B | $105.0M | +9.34% |
| Q1 2017 | 2017-03-31 | $1.14B | $196.0M | +20.72% |
| Q4 2016 | 2016-12-31 | $1.21B | $134.0M | +12.47% |
| Q3 2016 | 2016-09-30 | $1.11B | −$312.0M | −22.00% |
| Q2 2016 | 2016-06-30 | $1.12B | $143.0M | +14.58% |
| Q1 2016 | 2016-03-31 | $946.0M | $135.0M | +16.65% |
| Q4 2015 | 2015-12-31 | $1.07B | $196.0M | +22.30% |
| Q3 2015 | 2015-09-30 | $1.42B | $606.0M | +74.63% |
| Q2 2015 | 2015-06-30 | $981.0M | $147.0M | +17.63% |
| Q1 2015 | 2015-03-31 | $811.0M | $39.0M | +5.05% |
| Q4 2014 | 2014-12-31 | $879.0M | $81.0M | +10.15% |
| Q3 2014 | 2014-09-30 | $812.0M | $98.0M | +13.73% |
| Q2 2014 | 2014-06-30 | $834.0M | $125.0M | +17.63% |
| Q1 2014 | 2014-03-31 | $772.0M | $138.0M | +21.77% |
| Q4 2013 | 2013-12-31 | $798.0M | $117.0M | +17.18% |
| Q3 2013 | 2013-09-30 | $714.0M | −$99.0M | −12.18% |
| Q2 2013 | 2013-06-30 | $709.0M | $67.0M | +10.44% |
| Q1 2013 | 2013-03-31 | $634.0M | −$8.0M | −1.25% |
| Q4 2012 | 2012-12-31 | $681.0M | — | — |
| Q3 2012 | 2012-09-30 | $813.0M | — | — |
| Q2 2012 | 2012-06-30 | $642.0M | — | — |
| Q1 2012 | 2012-03-31 | $642.0M | — | — |
AbbVie r&d spending trends
Over the last five fiscal years, AbbVie's r&d spending increased from $6.38B to $9.10B, a change of $2.72B. The latest reported quarter, Q2 2026, shows $2.34B.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review AbbVie source filings ↗Community posts
AbbVie’s menstrual-migraine study meets its primary and all ranked secondary goals
AbbVie ($ABBV) reported positive Phase 3 LUNA results for atogepant in menstrual migraine. The study enrolled 468 women and evaluated treatment across three menstrual cycles. Migraine days during the assessed menstrual period fell by 1.20 d ...